Genetic and epigenetic events generate multiple pathways in colorectal cancer progression

Pathology Research International

Volumn 2012, Issue , 2012, Pages

  Pancione, Massimo ^a   Remo, Andrea ^b   Colantuoni, Vittorio ^a  

^a UNIVERSITY OF SANNIO   (Italy)

^b Mater Salutis Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866235428     PISSN: None     EISSN: 2042003X     Source Type: Journal    
DOI: 10.1155/2012/509348     Document Type: Article

References (93)

1. Cunningham D., Atkin W., Lenz H. J., Lynch H. T., Minsky B., Nordlinger B., Starling N., Colorectal cancer. The Lancet 2010 375 9719 1030 1047 2-s2.0-77949437015 10.1016/S0140-6736(10)60353-4
2. Tenesa A., Dunlop M. G., New insights into the aetiology of colorectal cancer from genome-wide association studies. Nature Reviews Genetics 2009 10 6 353 358 2-s2.0-67349245787 10.1038/nrg2574
3. Jemal A., Center M. M., Ward E., Thun M. J., Cancer occurrence. Methods in Molecular Biology 2009 471 3 29 2-s2.0-60349107336 10.1007/978-1-59745-416-21
4. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M. J., Cancer statistics, 2008. CA Cancer Journal for Clinicians 2008 58 2 71 96 2-s2.0-41349099104 10.3322/CA.2007.0010 (Pubitemid 351521864)
5. Sung J. J. Y., Lau J. Y. W., Goh K. L., Leung W. K., Chen M. H., Li C. J., Tandon R., Makharia G., Abdullah M., Fujita R., Hilmi I., Kim J. Y., Kim H. J., Yang S. K., Kim W. H., Kim T., Byeon J. S., Hilmi I., Sollano J., Ong E., Tan J., Ho L., Yeoh K. G., Wang C. Y., Wu D. C., Kongkam P., Kullavanijaya P., Increasing incidence of colorectal cancer in Asia: implications for screening. The Lancet Oncology 2005 6 11 871 876 2-s2.0-27744507676 10.1016/S1470-2045(05) 70422-8 (Pubitemid 41614799)
6. Rustgi A. K., The genetics of hereditary colon cancer. Genes and Development 2007 21 20 2525 2538 2-s2.0-35348992639 10.1101/gad.1593107 (Pubitemid 47607664)
7. Fearon E. R., Vogelstein B., A genetic model for colorectal tumorigenesis. Cell 1990 61 5 759 767 2-s2.0-0025312728 10.1016/0092-8674(90) 90186-I (Pubitemid 20185636)
8. Smith G., Carey F. A., Beattie J., Wilkie M. J. V., Lightfoot T. J., Coxhead J., Garner R. C., Steele R. J. C., Wolf C. R., Mutations in APC, Kirsten-ras, and p53alternative genetic pathways to colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America 2002 99 14 9433 9438 2-s2.0-0037047057 10.1073/pnas.122612899 (Pubitemid 34764631)
9. Ogino S., Goel A., Molecular classification and correlates in colorectal cancer. Journal of Molecular Diagnostics 2008 10 1 13 27 2-s2.0-37149041833 10.2353/jmoldx.2008.070082 (Pubitemid 351184831)
10. Jass J. R., Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007 50 1 113 130 2-s2.0-33845608798 10.1111/j.1365-2559.2006.02549.x (Pubitemid 44953403)
11. Markowitz S. D., Bertagnolli M. M., Molecular basis of colorectal cancer. The New England Journal of Medicine 2009 361 25 2404 2460 2-s2.0-72449176846 10.1056/NEJMra0804588
12. Young J., Jenkins M., Parry S., Young B., Nancarrow D., English D., Giles G., Jass J., Serrated pathway colorectal cancer in the population: genetic consideration. Gut 2007 56 10 1453 1459 2-s2.0-34948834584 10.1136/gut.2007. 126870 (Pubitemid 47517843)
13. Sharma S., Kelly T. K., Jones P. A., Epigenetics in cancer. Carcinogenesis 2009 31 1 27 36 2-s2.0-74049141478 10.1093/carcin/bgp220
14. Esteller M., Molecular origins of cancer: epigenetics in cancer. The New England Journal of Medicine 2008 358 11 1148 1096 2-s2.0-40849139208 10.1056/NEJMra072067 (Pubitemid 351398489)
15. Bonasio R., Tu S., Reinberg D., Molecular signals of epigenetic states. Science 2010 330 6004 612 616 2-s2.0-78049402859 10.1126/science.1191078
16. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation. Cell 2011 144 5 646 674 2-s2.0-79952284127 10.1016/j.cell.2011.02.013
17. Beckman R. A., Loeb L. A., Genetic instability in cancer: theory and experiment. Seminars in Cancer Biology 2005 15 6 423 435 2-s2.0-24944546620 10.1016/j.semcancer.2005.06.007 (Pubitemid 41318043)
18. Pino M. S., Chung D. C., The chromosomal instability pathway in colon cancer. Gastroenterology 2010 138 6 2059 2072 2-s2.0-77951627056 10.1053/j.gastro.2009.12.065
19. Boland C. R., Goel A., Microsatellite instability in colorectal cancer. Gastroenterology 2010 138 6 2073 2087 2-s2.0-77449130761 10.1053/j.gastro.2009. 12.064
20. Loeb L. A., Springgate C. F., Battula N., Errors in DNA replication as a basis of malignant changes. Cancer Research 1974 34 9 2311 2321 2-s2.0-0016176530
21. Klein C. A., Random mutations, selected mutations: a PIN opens the door to new genetic landscapes. Proceedings of the National Academy of Sciences of the United States of America 2006 103 48 18033 18034 2-s2.0-33845309647 10.1073/pnas.0609000103 (Pubitemid 44871607)
22. Toyota M., Ahuja N., Ohe-Toyota M., Herman J. G., Baylin S. B., Issa J. P. J., CpG island methylator phenotype in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America 1999 96 15 8681 8686 2-s2.0-0033587747 10.1073/pnas.96.15.8681 (Pubitemid 29354851)
23. Boland C. R., Komarova N. L., Goel A., Chromosomal instability and cancer: not just one CINgle mechanism. Gut 2009 58 2 163 164 2-s2.0-58849128292 10.1136/gut.2008.160143
24. Samowitz W. S., Albertsen H., Herrick J., Levin T. R., Sweeney C., Murtaugh M. A., Wolff R. K., Slattery M. L., Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005 129 3 837 845 2-s2.0-24144449572 10.1053/j.gastro.2005.06.020 (Pubitemid 41242676)
25. Issa J. P. J., Shen L., Toyota M., CIMP, at last. Gastroenterology 2005 129 3 1121 1124 2-s2.0-24144458254 10.1053/j.gastro.2005.07.040 (Pubitemid 41242702)
26. Curtin K., Slattery M. L., Samowitz W. S., CpG island methylation in colorectal cancer: past, present and future. Pathology Research International 2011 2011 8 902674 10.4061/2011/902674
27. Xu Y., Hu B., Choi A. J., Unique DNA methylome profiles in CpG island methylator phenotype colon cancers. Genome Research 2012 22 2 283 291
28. Hinoue T., Weisenberger D. J., Lange C. P., Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Research 2012 22 2 271 282 10.1101/gr.117523.110
29. Berman B. P., Weisenberger D. J., Aman J. F., Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nature Genetics 2012 44 1 40 46
30. Issa J. P., Colon cancer: it's CIN or CIMP. Clinical Cancer Research 2008 14 19 5939 5940
31. Shih I. M., Wang T. L., Traverso G., Romans K., Hamilton S. R., Ben-Sasson S., Kinzler K. W., Vogelstein B., Top-down morphogenesis of colorectal tumors. Proceedings of the National Academy of Sciences of the United States of America 2001 98 5 2640 2645 2-s2.0-0035956913 10.1073/pnas.051629398 (Pubitemid 32209535)
32. Feinberg A. P., Ohlsson R., Henikoff S., The epigenetic progenitor origin of human cancer. Nature Reviews Genetics 2006 7 1 21 33 2-s2.0-29244469466 10.1038/nrg1748 (Pubitemid 41828945)
33. Irizarry R. A., Ladd-Acosta C., Wen B., Wu Z., Montano C., Onyango P., Cui H., Gabo K., Rongione M., Webster M., Ji H., Potash J. B., Sabunciyan S., Feinberg A. P., The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nature Genetics 2009 41 2 178 186 2-s2.0-59149084538 10.1038/ng.298
34. Ohm J. E., McGarvey K. M., Yu X., Cheng L., Schuebel K. E., Cope L., Mohammad H. P., Chen W., Daniel V. C., Yu W., Berman D. M., Jenuwein T., Pruitt K., Sharkis S. J., Watkins D. N., Herman J. G., Baylin S. B., A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nature Genetics 2007 39 2 237 242 2-s2.0-33846569960 10.1038/ng1972 (Pubitemid 46184356)
35. Mohammad H. P., Cai Y., McGarvey K. M., Easwaran H., Van Neste L., Ohm J. E., O'Hagan H. M., Baylin S. B., Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specific DNA hypermethylation. Cancer Research 2009 69 15 6322 6330 2-s2.0-68049137611 10.1158/0008-5472.CAN-09-0065
36. Snover D. C., Update on the serrated pathway to colorectal carcinoma. Human Pathology 2011 42 1 1 10 2-s2.0-78649985198 10.1016/j.humpath.2010.06.002
37. Leggett B., Whitehall V., Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010 138 6 2088 2100 2-s2.0-77951647898 10.1053/j.gastro.2009.12.066
38. Dieter S. M., Ball C. R., Hoffmann C. M., Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011 9 4 375 365
39. Terzic J., Grivennicov S., Karin E., Karin M., Inflammation and colon cancer. Gastroenterology 2010 138 6 2101 2114 10.1053/j.gastro.2010.01.058
40. Feinberg A. P., Vogelstein B., Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983 301 5895 89 92 2-s2.0-0020699979 (Pubitemid 13154475)
41. Taft R. J., Pang K. C., Mercer T. R., Dinger M., Mattick J. S., Non-coding RNAs: regulators of disease. Journal of Pathology 2010 220 2 126 139 2-s2.0-73949085491 10.1002/path.2638
42. Portela A., Esteller M., Epigenetic modifications and human disease. Nature Biotechnology 2010 28 10 1057 1068 2-s2.0-77957970301 10.1038/nbt.1685
43. Pancione M., Sabatino L., Fucci A., Carafa V., Nebbioso A., Forte N., Febbraro A., Parente D., Ambrosino C., Normanno N., Altucci L., Colantuoni V., Epigenetic silencing of peroxisome proliferator- activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS ONE 2010 5 12, article e14229 2-s2.0-78649953952 10.1371/journal.pone.0014229
44. Chodavarapu R. K., Feng S., Bernatavichute Y. V., Chen P. Y., Stroud H., Yu Y., Hetzel J. A., Kuo F., Kim J., Cokus S. J., Casero D., Bernal M., Huijser P., Clark A. T., Krämer U., Merchant S. S., Zhang X., Jacobsen S. E., Pellegrini M., Relationship between nucleosome positioning and DNA methylation. Nature 2010 466 7304 388 392 2-s2.0-77954659099 10.1038/nature09147
45. Harikrishnan K. N., Chow M. Z., Baker E. K., Pal S., Bassal S., Brasacchio D., Wang L., Craig J. M., Jones P. L., Sif S., El-Osta A., Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nature Genetics 2005 37 3 254 264 2-s2.0-20144379888 10.1038/ng1516 (Pubitemid 41716252)
46. Reisman D., Glaros S., Thompson E. A., The SWI/SNF complex and cancer. Oncogene 2009 28 14 1653 1668 2-s2.0-64949113367 10.1038/onc.2009.4
47. Ho L., Ronan J. L., Wu J., Staahl B. T., Chen L., Kuo A., Lessard J., Nesvizhskii A. I., Ranish J., Crabtree G. R., An embryonic stem cell chromatin remodeling complex, esBAF, is essential for embryonic stem cell self-renewal and pluripotency. Proceedings of the National Academy of Sciences of the United States of America 2009 106 13 5181 5186 2-s2.0-65249180173 10.1073/pnas. 0812889106
48. Medina P. P., Sanchez Cespedes M., Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer. Epigenetics 2008 3 2 64 68 2-s2.0-47149101636
49. Reisman D. N., Strobeck M. W., Betz B. L., Sciariotta J., Funkhouser W., Murchardt C., Yaniv M., Sherman L. S., Knudsen E. S., Weissman B. E., Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene 2002 21 8 1196 1207 2-s2.0-0037075198 10.1038/sj/onc/1205188 (Pubitemid 34185236)
50. Wong A. K. C., Shanahan F., Chen Y., Lian L., Ha P., Hendricks K., Ghaffari S., Iliev D., Penn B., Woodland A. M., Smith R., Salada G., Carillo A., Laity K., Gupte J., Swedlund B., Tavtigian S. V., Teng D. H. F., Lees E., BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Research 2000 60 21 6171 6177 2-s2.0-0034326257
51. Bultman S., Gebuhr T., Yee D., La Mantia C., Nicholson J., Gilliam A., Randazzo F., Metzger D., Chambon P., Crabtree G., Magnuson T., A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. Molecular Cell 2000 6 6 1287 1295 2-s2.0-0034502484 10.1016/S1097-2765(00)00127-1 (Pubitemid 32045922)
52. Watanabe T., Semba S., Yokozaki H., Regulation of PTEN expression by the SWI/SNF chromatin-remodelling protein BRG1 in human colorectal carcinoma cells. British Journal of Cancer 2011 104 1 146 154 2-s2.0-78650898211 10.1038/sj.bjc.6606018
53. Sánchez-Tilló E., Lázaro A., Torrent R., Cuatrecasas M., Vaquero E. C., Castells A., Engel P., Postigo A., ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene 2010 29 24 3490 3500 2-s2.0-77953743748 10.1038/onc.2010.102
54. Yamamichi N., Inada K. I., Ichinose M., Yamamichi-Nishina M., Mizutani T., Watanabe H., Shiogama K., Fujishiro M., Okazaki T., Yahagi N., Haraguchi T., Fujita S., Tsutsumi Y., Omata M., Iba H., Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state. Cancer Research 2007 67 22 10727 10735 2-s2.0-36349006592 10.1158/0008-5472.CAN- 07-2601 (Pubitemid 350145899)
55. Sansam C. G., Roberts C. W. M., Epigenetics and cancer: altered chromatin remodeling via Snf5 loss leads to aberrant cell cycle regulation. Cell Cycle 2006 5 6 621 624 2-s2.0-33645279534
56. Sévenet N., Lellouch-Tubiana A., Schofield D., Hoang-Xuan K., Gessler M., Birnbaum D., Jeanpierre C., Jouvet A., Delattre O., Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Human Molecular Genetics 1999 8 13 2359 2368 2-s2.0-0345581429
57. Biegel J. A., Zhou J. Y., Rorke L. B., Stenstrom C., Wainwright L. M., Fogelgren B., Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Research 1999 59 1 74 79 2-s2.0-0032940605 (Pubitemid 29062960)
58. Roberts C. W. M., Biegel J. A., The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biology and Therapy 2009 8 5 412 416 2-s2.0-66149155091
59. Remo A., Zanella C., Molinari E., Rhabdoid carcinoma of the colon, a distinct entity with a very aggressive behaviour. A case report, associated with a polyposis coli and review of the Literature. International Journal of Surgical Pathology 2012 2 20 185 190
60. Pancione M., Di Blasi A., Sabatino L., Fucci A., Dalena A. M., Palombi N., Carotenuto P., Aquino G., Daniele B., Normanno N., Colantuoni V., A novel case of rhabdoid colon carcinoma associated with a positive CpG island methylator phenotype and BRAF mutation. Human Pathology 2011 42 7 1047 1052 2-s2.0-79959337448 10.1016/j.humpath.2010.10.016
61. Moinova H. R., Chen W. D., Shen L., Smiraglia D., Olechnowicz J., Ravi L., Kasturi L., Myeroff L., Plass C., Parsons R., Minna J., Willson J. K. V., Green S. B., Issa J. P., Markowitz S. D., HLTF gene silencing in human colon cancer. Proceedings of the National Academy of Sciences of the United States of America 2002 99 7 4562 4567 2-s2.0-18344368006 10.1073/pnas.062459899 (Pubitemid 34286024)
62. Popat S., Hubner R., Houlston R. S., Systematic review of microsatellite instability and colorectal cancer prognosis. Journal of Clinical Oncology 2005 23 3 609 618 2-s2.0-14544300998 10.1200/JCO.2005.01.086 (Pubitemid 46224239)
63. Lugli A., Zlobec I., Minoo P., Baker K., Tornillo L., Terracciano L., Jass J. R., Prognostic significance of the wnt signalling pathway molecules APC, β -catenin and E-cadherin in colorectal cancera tissue microarray-based analysis. Histopathology 2007 50 4 453 464 2-s2.0-33847324442 10.1111/j.1365-2559.2007.02620.x (Pubitemid 46328181)
64. Kalluri R., Weinberg R. A., The basics of epithelial-mesenchymal transition. Journal of Clinical Investigation 2009 119 6 1420 1428 2-s2.0-67650999875 10.1172/JCI39104
65. Clohessy J. G., Pandolfi P. P., β -tting on p63 as a Metastatic Suppressor. Cell 2009 137 1 28 30 2-s2.0-63249085192 10.1016/j.cell.2009.03.028
66. Moreno-Bueno G., Peinado H., Molina P., Olmeda D., Cubillo E., Santos V., Palacios J., Portillo F., Cano A., The morphological and molecular features of the epithelial-to-mesenchymal transition. Nature Protocols 2009 4 11 1591 1613 2-s2.0-73949150132
67. Guarino M., Rubino B., Ballabio G., The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007 39 3 305 318 2-s2.0-34250174504 10.1080/00313020701329914 (Pubitemid 46897605)
68. Larriba M. J., Casado-Vela J., Pendás-Franco N., Peña R., Herreros de A. G., Berciano M. T., Lafarga M., Casal J. I., Muñoz A., Novel snail1 target proteins in human colon cancer identified by proteomic analysis. PLoS ONE 2010 5 4, article e10221 2-s2.0-77956297936 10.1371/journal.pone.0010221
69. Moreno-Bueno G., Cubillo E., Sarrió D., Peinado H., Rodríguez-Pinilla S. M., Villa S., Bolós V., Jordá M., Fabra A., Portillo F., Palacios J., Cano A., Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for snail, Slug, and E47 Factors in epithelial- mesenchymal transition. Cancer Research 2006 66 19 9543 9556 2-s2.0-33750358078 10.1158/0008-5472.CAN-06-0479 (Pubitemid 44623653)
70. Amano M., Nakayama M., Kaibuchi K., Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton 2010 67 9 545 554 2-s2.0-78149353346 10.1002/cm.20472
71. Ortega P., Morán A., De Juan C., Frías C., Hernández S., López-Asenjo J. A., Sánchez-Pernaute A., Torres A., Iniesta P., Benito M., Differential Wnt pathway gene expression and E-cadherin truncation in sporadic colorectal cancers with and without microsatellite instability. Clinical Cancer Research 2008 14 4 995 1001 2-s2.0-39749167839 10.1158/1078-0432.CCR-07-1588 (Pubitemid 351302544)
72. Suzuki H., Masuda N., Shimura T., Araki K., Kobayashi T., Tsutsumi S., Asao T., Kuwano H., Nuclear β -catenin expression at the invasive front and in the vessels predicts liver metastasis in colorectal carcinoma. Anticancer Research 2008 28 3 1821 1830 2-s2.0-45949094481 (Pubitemid 351892891)
73. Horst D., Reu S., Kriegl L., Engel J., Kirchner T., Jung A., The intratumoral distribution of nuclear β -catenin is a prognostic marker in colon cancer. Cancer 2009 115 10 2063 2070 2-s2.0-65649146135 10.1002/cncr.24254
74. Pancione M., Forte N., Fucci A., Sabatino L., Febbraro A., Di Blasi A., Daniele B., Parente D., Colantuoni V., Prognostic role of β -catenin and p53 expression in the metastatic progression of sporadic colorectal cancer. Human Pathology 2010 41 6 867 876 2-s2.0-77951938523 10.1016/j.humpath.2009.09. 019
75. García-Solano J., Conesa-Zamora P., Trujillo-Santos J., Immunohistochemical expression profile of β -catenin, E-cadherin, P-cadherin, laminin-5 γ 2 chain, and SMAD4 in colorectal serrated adenocarcinoma. Human Pathology 2012 43 7 1094 1102
76. Pino M. S., Kikuchi H., Zeng M., Herraiz M. T., Sperduti I., Berger D., Park D. Y., Iafrate A. J., Zukerberg L. R., Chung D. C., Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology 2010 138 4 1406 1417 2-s2.0-77949845438 10.1053/j.gastro.2009.12.010
77. Kang G. H., Four molecular subtypes of colorectal cancer and their precursor lesions. Archives of Pathology and Laboratory Medicine 2011 135 6 698 703 2-s2.0-79958806016
78. Bae J. M., Kim M. J., Kim J. H., Koh J. M., Cho N. Y., Kim T. Y., Kang G. H., Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status. Virchows Archiv 2011 459 1 55 63 2-s2.0-79959992817 10.1007/s00428-011-1080-3
79. Jorissen R. N., Gibbs P., Christie M., Prakash S., Lipton L., Desai J., Kerr D., Aaltonen L. A., Arango D., Kruhoffer M., Orntoft T. F., Andersen C. L., Gruidl M., Kamath V. P., Eschrich S., Yeatman T. J., Sieber O. M., Metastasis-associated gene expression changes predict poor outcomes in patients with Dukes stage B and C colorectal cancer. Clinical Cancer Research 2009 15 24 7642 7651 2-s2.0-73349088103 10.1158/1078-0432.CCR-09-1431
80. Smith J. J., Deane N. G., Wu F., Merchant N. B., Zhang B., Jiang A., Lu P., Johnson J. C., Schmidt C., Bailey C. E., Eschrich S., Kis C., Levy S., Washington M. K., Heslin M. J., Coffey R. J., Yeatman T. J., Shyr Y., Beauchamp R. D., Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010 138 3 958 968 2-s2.0-77249143960 10.1053/j.gastro.2009.11.005
81. Loboda A., Nebozhyn M. V., Watters J. W., Buser C. A., Shaw P. M., Huang P. S., Van'T Veer L., Tollenaar R. A., Jackson D. B., Agrawal D., Dai H., Yeatman T. J., EMT is the dominant program in human colon cancer. BMC Medical Genomics 2011 4, article 9 2-s2.0-78651529782 10.1186/1755-8794-4-9
82. Prall F., Tumour budding in colorectal carcinoma. Histopathology 2007 50 1 151 162 2-s2.0-33845599552 10.1111/j.1365-2559.2006.02551.x (Pubitemid 44953405)
83. Karamitopoulou E., Lugli A., Panayiotides I., Karakitsos P., Peros G., Rallis G., Patsouris E. S., Terracciano L., Zlobec I., Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer. Histopathology 2010 57 2 233 243 2-s2.0-77955838050 10.1111/j.1365-2559.2010.03615.x
84. Zlobec I., Molinari F., Martin V., Mazzucchelli L., Saletti P., Trezzi R., de Dosso S., Vlajnic T., Frattini M., Lugli A., Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World Journal of Gastroenterology 2010 16 38 4823 4831 2-s2.0-78049495404 10.3748/wjg.v16.i38.4823
85. Zlobec I., Lugli A., Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010 1 7 651 661 2-s2.0-79958003343
86. Samowitz W. S., Sweeney C., Herrick J., Albertsen H., Levin T. R., Murtaugh M. A., Wolff R. K., Slattery M. L., Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Research 2005 65 14 6063 6070 2-s2.0-22244472992 10.1158/0008-5472.CAN-05-0404 (Pubitemid 40994390)
87. Kim M. S., Lee J., Sidransky D., DNA methylation markers in colorectal cancer. Cancer and Metastasis Reviews 2010 29 1 181 206 2-s2.0-77349107376 10.1007/s10555-010-9207-6
88. Grady W. M., Carethers J. M., Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008 135 4 1079 1099 2-s2.0-53049087109 10.1053/j.gastro.2008.07.076
89. Wong J. J. L., Hawkins N. J., Ward R. L., Hitchins M. P., Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer. Modern Pathology 2011 24 3 396 411 2-s2.0-79952191728 10.1038/modpathol.2010.212
90. Georgiades I. B., Curtis L. J., Morris R. M., Bird C. C., Wyllie A. H., Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability. Oncogene 1999 18 56 7933 7940 2-s2.0-0033598978 (Pubitemid 30050553)
91. English D. R., Young J. P., Simpson J. A., Jenkins M. A., Southey M. C., Walsh M. D., Buchanan D. D., Barker M. A., Haydon A. M., Royce S. G., Roberts A., Parry S., Hopper J. L., Jass J. J., Giles G. G., Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiology Biomarkers and Prevention 2008 17 7 1774 1780 2-s2.0-53549108607 10.1158/1055-9965.EPI-08-0091
92. Rozek L. S., Herron C. M., Greenson J. K., Moreno V., Capella G., Rennert G., Gruber S. B., Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiology Biomarkers and Prevention 2010 19 3 838 843 2-s2.0-77949714884 10.1158/1055-9965.EPI-09-1112
93. Ogino S., Nosho K., Kirkner G. J., Kawasaki T., Meyerhardt J. A., Loda M., Giovannucci E. L., Fuchs C. S., CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009 58 1 90 96 2-s2.0-58249089525 10.1136/gut.2008.155473